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Abstract
Manipur and Nagaland in northeast India report an antenatal HIV prevalence of > 1% and the
current HIV prevalence among injecting drug users is 24% and 4.5% respectively. Through support
from DFID's Challenge Fund, Emmanuel Hospital Association (EHA) established thirteen drop-in-
centres across the two states to deliver opioid substitution treatment with sublingual
buprenorphine for 1200 injecting drug users. Within a short span of time the treatment has been
found to be attractive to the clients and currently 1248 injecting opioid users are receiving opioid
substitution treatment. The project is acceptable to the drug users, the families, the communities,
religious as well as the militant groups. The treatment centres operate all days of the week, have
trained staff members, utilize standardized protocols and ensure a strict supervised delivery system
to prevent illicit diversion of buprenorphine. The drug users receiving the substitution treatment
are referred to HIV voluntary counselling and testing. As this treatment has the potential to change
HIV related risk behaviours, what has been established in the two states needs to be continued and
expanded with the support from the Government of India.
Findings
In the early 1980s injecting heroin became popular in
northeast India, sharing border with Myanmar and since
then injecting has diffused extensively into many states of
northeast India [1,2]. Recent size estimation data show
that injecting drug users (IDUs) could constitute 1·9–
2·7% of the adult population in Manipur and Nagaland
[3]. Ever since HIV was first reported among IDUs in
Manipur, HIV infection has rapidly diffused and escalated
among the IDUs in the region [4-6]. The HIV prevalence
among IDUs during the 2002, 2003, 2004 and 2005 sero
sentinel surveillance was estimated at 39%, 24.5%, 21%,
24% in Manipur and 10%, 8.4%, 3.2%, 4.5% in Nagaland
respectively [7]. Sexual transmission of HIV from IDUs to
their non-injecting wives has occurred in Manipur [8].
Manipur and Nagaland in northeast India are among the
high prevalent HIV states in India and the antenatal HIV
prevalence in both states is > 1% [7,9]. The community
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outreach based interventions for IDUs have been estab-
lished since early 1990s [10]. Harm reduction interven-
tions have been advocated in the northeastern states to
deal with the increasing HIV epidemic among IDUs and
they have been driven by community based organizations
run by former drug users [11-13]. The targeted interven-
tions supported by the State AIDS Control Societies focus
on community outreach based education; distribution of
needles and syringes and condoms; and, referral for vol-
untary confidential, counselling and testing (VCCT).
Methadone is not available in India for clinical use since
the time it was taken off the Indian pharmacopoeia in
1982. Sublingual buprenorphine is licensed in India for
treatment of opioid dependence by drug abuse treatment
centres since 1999 [14]. Though an opioid substitution
treatment (OST) with sublingual buprenorphine was
established and operated in Imphal, Manipur by a non-
Governmental organization (NGO) during 1999–2002
targeting about 250 IDUs, the lessons learnt from the
project were not documented in detail.
It is evident from the rapid assessments carried out in
Manipur that injecting drug users preferred OST [15].
Having understood the need from the drug using popula-
tions in the Northeastern States of India, the Emmanuel
Hospital Association (EHA) of India successfully applied
for a grant from the DFID Challenge Fund [16] in order to
establish OST for opioid injectors in the states of Manipur
and Nagaland. EHA identified NGOs working with drug
users in Manipur (n = 7) and Nagaland (n = 4) to establish
OST in nine drop-in-centres (DICs) in Manipur and four
DICs in Nagaland to cover a target of 1200 IDUs. Five
months after the initiation of the opioid substitution
treatment, a mid-term evaluation was carried out by two
external consultants during the month of October 2006.
The methods of evaluation included personal visits to the
DICs for observation, in-depth interviews with the staff of
the DICs and focus group discussions (FGDs) with the cli-
ents attending the services as well as review of all relevant
documentation.
In addition, two workshops were held in which the pro-
gram managers presented the findings of the project based
on a standardized format provided to them earlier. Dur-
ing the workshop, small group discussions were held with
the various groups of program managers, health care
workers and outreach workers in order to identify the
challenges and possible future directions.
Table 1 describes some of the findings of the evaluation.
In all the sites the number of drug users attending the serv-
ices exceeded the targeted number. In-depth interviews
indicate that within a few days of initiation of the treat-
ment project, the treatment slots were filled. A total of 451
opioid users are on the waitlist as of 30th Sept 2006. The
primary drugs of use in the drug users seeking substitution
treatment in Manipur are: heroin (560/844; 66.4%); a
combination of heroin and dextropropoxyphene (207/
844; 24.5%) and dextropropoxyphene alone (77/844;
9.1%). In Nagaland, the primary drugs of use are: a com-
bination of the adulterated heroin [brown sugar] and dex-
tropropoxyphene (197/404; 48.8%),
dextropropoxyphene alone (160/404; 39.6%), followed
by brown sugar (47/404; 11.6%). The number of women
drug users in treatment is low (102/1248; 8.2%) and only
one of the thirteen DICs is targeting women drug users
and their regular sex partners. A total of 446 opioid users
(446/1353; 33%) in Manipur and 106 opioid users (106/
537; 19.7%) in Nagaland dropped out after commencing
treatment. The reasons for drop-out identified through
FGDs are:
￿ Distance of the DICs from the residence of the drug
users,
￿ Difficulty in follow-up due to either the wrong addresses
provided by the drug users or the limited number of out-
reach staff in the projects.
The treatment is delivered through a protocol adapted
from the guidelines developed by UNODC ROSA [17].
Doctors, either full time or part time are available in all
the DICs. The average maintenance dose is 4–8 mg in 12
of the 13 DICs; in one centre in Nagaland, the average
dose is 12 mg. All the thirteen DICs provide sublingual
buprenorphine tablets strictly under supervision. The
medicine is crushed and administered underneath the
tongue by the health care worker and the patients are
asked to stay on the premises for 15 minutes after admin-
istration of the drug. All DICs operate 7 days a week and
the dispensing time is from morning until afternoon in
eight DICs, whilst the remaining five operate from morn-
ing through to the evening. Six of the nine DICs in
Manipur allow take home doses that are not exceeding
three days save for in exceptional cases (e.g., visit to village
to attend a death or marriage of a close relative); the take
home doses are given to a family member.
The other services provided to all drug users in the DICs
are: condoms, STI treatment, wound care and primary
medical care. A total of 257 (257/844; 30.5%) and 16
(16/404; 4%) drug users on substitution treatment in
Manipur and Nagaland respectively, were aware of their
HIV status at the time of recruitment. Since initiating
buprenorphine treatment, 260 drug users (260/844;
30.8%) in Manipur and 38 drug users (38/404; 9.4%) in
Nagaland have been referred for VCCT. Of the drug users
receiving treatment, 4.7% (59/1248) have been referred
for Antiretroviral Treatment (ART). The other referrals that
are offered to the drug users include: assessing liver func-Harm Reduction Journal 2009, 6:4 http://www.harmreductionjournal.com/content/6/1/4
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Table 1: Opioid users under treatment with sublingual buprenorphine in the northeastern states of Manipur and Nagaland, India
Name of 
NGO
Target Waitlist Currently under 
treatment
Primary drug of use HIV testing and ART treatment
Total Females 
(%)
Heroin or 
brown 
sugar
Dextropr
opoxyphe
ne
Combinat
ion
HIV 
status 
known
Ref for 
VCCT
Ref for 
ART
Manipur
Care 
Foundation 
(Imphal)
100 51 91 3 (3.3%) 80 (87.9%) 11 (12.1%) 0 (0%) 49 (53.8%) 56 (61.5%)‡ 7 (7.7%)
Care 
Foundation 
(Nambol)
75 0 60 1 (1.7%) 31(51.7%) 25 (41.7%) 4 (6.7%) 9 (15%) 35 (58.3%) 0 (0%)
DPU 75 25 94 3 (3.2%) 63 (67%) 0 (0%) 31 (33%) 24 (25.5%) 24 (25.5%) 2 (2.1%)
MNP+ 100 150 102 0 (0%) 80 (78.4%) 7 (68.6%) 15 (14.7%) 65 (63.7%) 32 (31.4%) 9 (8.8%)
Ramungo 
Library
75 0 77 0 (0%) 4 (5.2%) 4 (5.2%) 69 (89.6%) 6 (7.8%) 21(27.3%) 2 (2.6%)
SASO (East) 100 30 100 0 (0%) 61 (61%) 4 (4%) 35 (35%) 32 (32%) 15 (15%) 1 (1%)
SASO 
(West)
100 27 100 2 (2%) 72 (72%) 10 (10%) 18 (18%) 26 (26%) 19 (19%) 6 (6%)
Sahara 100 0 110 7 (6.4%) 101(91.8%) 4 (3.7%) 5 (4.5%) 44 (40%) 35 (31.8%) 23 ((20.9%)
SHALOM 100 0 110 7 (6.4%) 68 (61.8%) 12 (10.9%) 30 (27.3%) 2 (1.8%) 23 (20.9%) 9 (8.2%)
Manipur 
Total
825 283 844 23 (2.7%) 560 
(66.4%)
77 (9.1%) 207 
(24.5%)
257 
(30.5%)
260 
(30.8%)
59 (7%)
Nagaland
Bethesda 
(IDU)
100 168 114 0 (0%) 0 (0%) 1 (0.9%) 113 
(99.1%)
3 (2.6%) 15 (13.2%) 0 (0%)
Bethesda 
(IDUSW)
100 0 106 79 (73.1%) 16 (15.1%) 12 (11.3%) 78 (73.6%) 13 (12.3%) 12 (11.3%) 0 (0%)
Bethesda- 
Pfutsero
75 0 60 0 (0%) 0 (0%) 54 (90%) 6 (10%) 0 (0%) 0 (0%) 0 (0%)
Kripa 
Foundation
100 0 124 0 (0%) 31(25%) 93 (75%) 0 (0%) 0 (0%) 11 (8.9%) 0 (0%)
Nagaland 
Total
375 168 404 79 (19.6%) 47 (11.6%) 160 
(39.6%)
197 
(48.8%)
16 (4%) 38 (9.4%) 0 (0%)
Grand 
Total
1200 451 1248 102 (8.2%) 607 
(48.6%)
237 (19%) 404 
(32.4%)
273 
(21.9%)
298 
(23.9%)
59 (4.7%)Harm Reduction Journal 2009, 6:4 http://www.harmreductionjournal.com/content/6/1/4
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tion tests, STI treatment and TB treatment. A total of 109
drug users (109/1248; 8.7%) have been referred for absti-
nence oriented treatment.
The majority of staff members (96/110; 87.2%) are
trained in OST. All the treatment centres have facilitated
the formation of support groups and many of the regular
clients serve as peer volunteers and help with patient edu-
cation, DIC maintenance and cleanliness of the surround-
ings. All the DICs have carried out advocacy with the
community, particularly the neighborhood; two DICs in
Nagaland and one DIC in Manipur have advocated with
underground militants and obtained support from them
to carry out the project without any interference. Two
DICs each in Manipur and Nagaland have carried out
advocacy with the police. Three DICs have advocated with
policy makers and health professionals.
Within a short span of time, all DICs have recruited opi-
oid users without the active help of the outreach workers
and inducted them into OST. The treatment is attractive to
clients as indicated by the wait-list in all of the DICs. OST
is acceptable to all stakeholders – drug users, families of
drug users, religious leaders, law enforcement and the
underground militants, and this a key factor for enabling
the DICs to operate without a hitch in all the places. The
trained staff members, utilization of standardized proto-
cols by the medical doctors and the help of the peer vol-
unteers facilitate a good process for the delivery of OST. A
strict supervised delivery system ensures that there is no
illicit diversion of the drug. While on OST, the drug users
are able to utilize HIV voluntary counselling and testing
services. The data on behavioural changes is being col-
lected and will be analysed at the end of a year following
the establishment of OST. The project must address issues
relating to retention and the further improvement of
retention rates. Retention rates can be improved by pro-
viding improved access to transportation, encouraging the
drug-users to provide correct personal information and by
increasing the number of outreach workers in each DIC to
do follow-up work.
The primary concern expressed by the drug users and the
staff members is the issue of sustainability. Given that the
project is attractive, acceptable and capable of providing a
range of prevention and care services for the drug users
while on OST, it is vital that there be a continuity of the
services that have been established. While the National
AIDS Control Organization (NACO) in India is contem-
plating scaling up prevention and care services for IDUs in
the next phase of programme implementation, lessons
learnt from the OST projects in the two states is of
immense value. The projects have demonstrated that
community based organizations can establish OST that
can serve the drug users in user-friendly settings that can
offer a continuum of prevention and care services through
effective linkages and referrals to existing health services.
What is required is policy advocacy to ensure that the drug
users have access to the drugs like buprenorphine, an
essential drug listed by the WHO [18], with less adverse
effects [19] and that can potentially change HIV-related
behaviours, reduce crime and improve quality of life [20-
25]. As a first step in this advocacy process, the findings of
this evaluation were reported to the joint meeting of the
NACO and the partner NGOs working with IDUs in India
with funding support from DFID held on the November
17–18, 2006 at New Delhi. What has been established
needs to be continued as well as expanded in future.
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